AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33843952 — intervention group
Group type: EXPERIMENTAL
Intervention: AD genetic risk score (AD-GRS)
Number of subjects: 0
Study 36207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive labels
Number of subjects: 3051
Study 36207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative labels
Number of subjects: 3051
Study 36207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positive and negative labels
Number of subjects: 3051
Study 36207203 — intervention group
Group type: EXPERIMENTAL
Intervention: Only negative labels
Number of subjects: 3051
Study 36207203 — intervention group
Group type: COMPARATOR
Intervention: Control (calorie)
Number of subjects: 3051
Study 33541751 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 304
Study 33541751 — intervention group
Group type: COMPARATOR
Intervention: B-mode ultrasound with normal saline
Number of subjects: 304
Study 33541751 — intervention group
Group type: COMPARATOR
Intervention: Empirical diagnosis
Number of subjects: 304
Study 33541751 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography
Number of subjects: 304
Study 33541751 — intervention group
Group type: COMPARATOR
Intervention: B-mode ultrasound
Number of subjects: 304
Study 32544602 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant clinician (CC)
Number of subjects: 66
Study 32544602 — intervention group
Group type: COMPARATOR
Intervention: Discordant clinician (DC)
Number of subjects: 66
Study 36201360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 30 mg
Number of subjects: 140
Study 36201360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 80 mg
Number of subjects: 140
Study 33559410 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 0
Study 33559410 — intervention group
Group type: COMPARATOR
Intervention: Routine Surveillance (RS)
Number of subjects: 0
Study 33136423 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP T1D
Number of subjects: 264
Study 33136423 — intervention group
Group type: COMPARATOR
Intervention: Education Intervention (EI)
Number of subjects: 264
Study 36172298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume PEG plus senna
Number of subjects: 382
Study 36172298 — intervention group
Group type: COMPARATOR
Intervention: High volume PEG
Number of subjects: 382
Study 33562774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-1
Number of subjects: 0
Study 33562774 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated data with varying intervals (12 and 35 days)
Number of subjects: 0
Study 33562774 — intervention group
Group type: COMPARATOR
Intervention: ERS and Envisat results
Number of subjects: 0
Study 34053249 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) plus traditional physical therapy program (TPTP)
Number of subjects: 40
Study 34053249 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program (TPTP)
Number of subjects: 40
Study 35236281 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)-based algorithm
Number of subjects: 0
Study 35236281 — intervention group
Group type: COMPARATOR
Intervention: No algorithm
Number of subjects: 0
Study 32548638 — intervention group
Group type: EXPERIMENTAL
Intervention: GSSO ontology version 2
Number of subjects: 0
Study 34996786 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy blended with six online modules of pain education and behavioural activation
Number of subjects: 0
Study 34996786 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy
Number of subjects: 0
Study 33651414 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment for Bell's palsy
Number of subjects: 0
Study 33651414 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study 32605059 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating pattern
Number of subjects: 1919
Study 32605059 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Sweet and Beverages pattern
Number of subjects: 1919
Study 32605059 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Salty and Alcohol pattern
Number of subjects: 1919
Study 35362666 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned delivery
Number of subjects: 901
Study 35362666 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 901
Study 32651477 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 221
Study 32651477 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 221
Study 32251813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal full endoscopic lumbar discectomy (FELD)
Number of subjects: 50
Study 32251813 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy (OD)
Number of subjects: 50
Study 32251813 — intervention group
Group type: EXPERIMENTAL
Intervention: FELD
Number of subjects: 50
Study 32251813 — intervention group
Group type: COMPARATOR
Intervention: OD
Number of subjects: 50
Study 36288584 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB with IV dexamethasone (DEX1)
Number of subjects: 105
Study 36288584 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB with dexamethasone (DEX2)
Number of subjects: 105
Study 36288584 — intervention group
Group type: COMPARATOR
Intervention: QLB alone (CONTROL)
Number of subjects: 105
Study 34870067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym and PT
Number of subjects: 19
Study 34870067 — intervention group
Group type: COMPARATOR
Intervention: Gym only
Number of subjects: 19
Study 34648897 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized in-person advance care planning (ACP) sessions delivered by nurses or social workers with nephrology or palliative care experience.
Number of subjects: 254
Study 34648897 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control group received Make Your Wishes About You (MY WAY) education materials and encouragement to bring completed advance directives.
Number of subjects: 254
Study 33371976 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral Skills Model interventions
Number of subjects: 50
Study 35618342 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 38443
Study 35618342 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 38443
Study 32277800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment protocol for children and adolescents (PE‐A)
Number of subjects: 37
Study 36453018 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based manipulable pelvic bone model
Number of subjects: 0
Study 36453018 — intervention group
Group type: COMPARATOR
Intervention: Online static images of the same model
Number of subjects: 0
Study 36453018 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulable model-based posttest
Number of subjects: 0
Study 36453018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental effort scores
Number of subjects: 0
Study 32537711 — intervention group
Group type: COMPARATOR
Intervention: Continuation of oral antibiotics (standard arm)
Number of subjects: 75
Study 32537711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoppage of antibiotics (experimental arm)
Number of subjects: 75
Study 35777275 — intervention group
Group type: EXPERIMENTAL
Intervention: 324 mg of VTS‐Aspirin™ and 0.5 mg/kg of oral ketamine (AOK)
Number of subjects: 60
Study 35777275 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg of oral ketamine (OK)
Number of subjects: 60
Study 35777275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AOK and OK)
Number of subjects: 60
Study 32553881 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RPT/INH (rifapentine and isoniazid)
Number of subjects: 513
Study 32553881 — intervention group
Group type: COMPARATOR
Intervention: Observation (untreated)
Number of subjects: 513
Study 32270632 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy
Number of subjects: 100
Study 32270632 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy (control group)
Number of subjects: 100
Study 33208009 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 12
Study 33208009 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 34034365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-TSH group (target TSH levels between 2.0 and 7.99 μIU/mL)
Number of subjects: 2986
Study 34034365 — intervention group
Group type: COMPARATOR
Intervention: Low-TSH group (target TSH levels between 0.3 and 1.99 μIU/mL)
Number of subjects: 2986
Study 34034365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-TSH group
Number of subjects: 2986
Study 34034365 — intervention group
Group type: COMPARATOR
Intervention: Low-TSH group
Number of subjects: 2986
Study 32033610 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal-phase ovarian stimulation (LPOS)
Number of subjects: 60
Study 32033610 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase ovarian stimulation (FPOS)
Number of subjects: 60
Study 36402359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IMRT (59.4 Gy)
Number of subjects: 167
Study 36402359 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose IMRT (50.4 Gy)
Number of subjects: 167
Study 33555374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-enriched Leberkas meal (19.2 g of wheat fibre and resistant dextrin, fat- and energy-reduced by 30%)
Number of subjects: 20
Study 33555374 — intervention group
Group type: COMPARATOR
Intervention: Standard Leberkas meal
Number of subjects: 20
Study 35470188 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiotherapy combined with S‐1 and nedaplatin chemotherapy (50.4 Gy + 4-6 cycles of S-1 and NPD)
Number of subjects: 180
Study 35470188 — intervention group
Group type: COMPARATOR
Intervention: S‐1 and nedaplatin chemotherapy (4-6 cycles)
Number of subjects: 180
Study 34810107 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training + sensorimotor physical therapy (45 min sensorimotor + 15 min inspiratory muscle training for 18 sessions over six weeks)
Number of subjects: 40
Study 34810107 — intervention group
Group type: COMPARATOR
Intervention: Control group (45 min sensorimotor training session, three times a week over six weeks)
Number of subjects: 40
Study 35162053 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable unilateral horizontal movements (VUH, n = 12)
Number of subjects: 24
Study 35162053 — intervention group
Group type: COMPARATOR
Intervention: Unilateral lateral movements (VUL, n = 12)
Number of subjects: 24
Study 34041615 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (six-step music therapy), n=50
Number of subjects: 100
Study 32886650 — intervention group
Group type: EXPERIMENTAL
Intervention: Actiwatch 2 (AW2)
Number of subjects: 50
Study 35030278 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS
Number of subjects: 38
Study 35030278 — intervention group
Group type: COMPARATOR
Intervention: CS
Number of subjects: 38
Study 32427726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular surgery (specifically strabismus, cornea, and glaucoma surgeries)
Number of subjects: 8297
Study 32427726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 8297
Study 32427726 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II diabetes
Number of subjects: 8297
Study 32205463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (30 Gy in 10 fractions)
Number of subjects: 20
Study 32205463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (27 Gy in 3 fractions)
Number of subjects: 20
Study 32205463 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical data of nivolumab and ipilimumab alone)
Number of subjects: 20
Study 35028919 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 67
Study 35028919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WBV)
Number of subjects: 67
Study 34061144 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab (375 mg/m2/wk, 4 doses)
Number of subjects: 140
Study 34061144 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisolone (1 mg/kg/d) plus rituximab
Number of subjects: 140
Study 34061144 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab
Number of subjects: 140
Study 34987204 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-directed behavioral weight loss on a DASH diet
Number of subjects: 121
Study 34987204 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 121
Study 34987204 — intervention group
Group type: COMPARATOR
Intervention: Self-directed care (control)
Number of subjects: 121
Study 32334034 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2) plus IG‐IMRT (45‐47.6 Gy, 25‐28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2‐59.4 Gy, 28 fractions)
Number of subjects: 35
Study 32334034 — intervention group
Group type: EXPERIMENTAL
Intervention: IG‐IMRT with concurrent chemotherapy
Number of subjects: 35
Study 33092420 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (cord clamped in 30–45 s)
Number of subjects: 148
Study 33092420 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (cord clamped in 10–15 s)
Number of subjects: 148
Study 35109906 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydrogen peroxide
Number of subjects: 0
Study 35109906 — intervention group
Group type: COMPARATOR
Intervention: Topical fusidic acid
Number of subjects: 0
Study 35109906 — intervention group
Group type: COMPARATOR
Intervention: Simple wound care
Number of subjects: 0
Study 33171113 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte‐ and platelet‐rich fibrin (L‐PRF)
Number of subjects: 16
Study 33171113 — intervention group
Group type: COMPARATOR
Intervention: Blood clot
Number of subjects: 16
Study 35236391 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine sulphate 5 mg twice daily for 14 days
Number of subjects: 44
Study 35236391 — intervention group
Group type: COMPARATOR
Intervention: placebo twice daily
Number of subjects: 44
Study 32961255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 645
Study 32961255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 645
Study 32961255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Number of subjects: 645
Study 32633901 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) - eight sessions of twice-weekly training (n=49)
Number of subjects: 79
Study 32633901 — intervention group
Group type: COMPARATOR
Intervention: Sham training (n=21)
Number of subjects: 79
Study 32633901 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 79
Study 33246252 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hypertonic saline (HS)
Number of subjects: 14
Study 33246252 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol
Number of subjects: 14
Study 32216084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) administered in two equally divided doses over two nights; dose 1 was half of dose 2, administered > 2 hours after the evening meal and ≥ 4 hours after dose 1.
Number of subjects: 29
Study 32216084 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK model established combining current study data with prior data from adults (132 healthy volunteers and 13 with narcolepsy).
Number of subjects: 29
Study 34519560 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Mountain delivered in small groups
Number of subjects: 81
Study 34519560 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Mountain delivered individually
Number of subjects: 81
Study 34519560 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 81
Study 34421047 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling-based intervention (ST)
Number of subjects: 585
Study 34421047 — intervention group
Group type: COMPARATOR
Intervention: Didactic learning (DL)
Number of subjects: 585
Study 36054974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine HCl (4 mg BID to 8 mg TID over 3 weeks)
Number of subjects: 94
Study 36054974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched doses)
Number of subjects: 94
Study 36041912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 36041912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 32503392 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) group
Number of subjects: 18
Study 32503392 — intervention group
Group type: COMPARATOR
Intervention: Videoconferencing (VC) group
Number of subjects: 18
Study 32108274 — intervention group
Group type: EXPERIMENTAL
Intervention: Item imputation
Number of subjects: 0
Study 32108274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate imputation
Number of subjects: 0
Study 36130482 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose feeding
Number of subjects: 0
Study 36130482 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 34294219 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior endonasal dacryorhinocystostomy (Group A)
Number of subjects: 30
Study 34294219 — intervention group
Group type: COMPARATOR
Intervention: Posterior endonasal dacryorhinocystostomy (Group B)
Number of subjects: 30
Study 32803720 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line doublet chemotherapy with bevacizumab
Number of subjects: 867
Study 32803720 — intervention group
Group type: COMPARATOR
Intervention: First-line doublet chemotherapy without bevacizumab
Number of subjects: 867
Study 35831055 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia information (MMI) group; n=681
Number of subjects: 1409
Study 35831055 — intervention group
Group type: COMPARATOR
Intervention: Printed participant information sheet (PIS) group; n=728
Number of subjects: 1409
Study 35831055 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI group
Number of subjects: 1409
Study 35831055 — intervention group
Group type: COMPARATOR
Intervention: PIS group
Number of subjects: 1409
Study 33246371 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program delivered via video conferencing technology
Number of subjects: 0
Study 33246371 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program delivered via inmate co-facilitated formats
Number of subjects: 0
Study 33246371 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking for a Change cognitive behavioral program with greater program dosage
Number of subjects: 0
Study 33246371 — intervention group
Group type: EXPERIMENTAL
Intervention: Program completion
Number of subjects: 0
Study 33246371 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom administration of the Thinking for a Change program
Number of subjects: 0
Study 32827441 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PTH levels
Number of subjects: 361194
Study 36121664 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with PSA ≥3 to 4 ng/ml
Number of subjects: 46495
Study 36121664 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with PIRADS score ≤ 2
Number of subjects: 46495
Study 36121664 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with a history of digital rectal examination or PSA testing prior to recruitment
Number of subjects: 46495
Study 33611087 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg regular, oral sustained-release morphine twice daily for four weeks
Number of subjects: 106
Study 33611087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 32891871 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS to frontal (F4)
Number of subjects: 80
Study 32891871 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS to parietal (P4)
Number of subjects: 80
Study 32891871 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS alternating (P4–F4)
Number of subjects: 80
Study 32891871 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (P4 or F4)
Number of subjects: 80
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (Group-2, n = 241)
Number of subjects: 677
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole with other antifungal prophylaxis (Group-3, n = 142)
Number of subjects: 677
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antifungal prophylaxis (Group-4, n = 91)
Number of subjects: 677
Study 34895843 — intervention group
Group type: COMPARATOR
Intervention: No antifungal prophylaxis (Group-1, n = 203)
Number of subjects: 677
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 677
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: IFI occurrence
Number of subjects: 677
Study 34895843 — intervention group
Group type: EXPERIMENTAL
Intervention: AML complete remission
Number of subjects: 677
Study 32694343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n=15)
Number of subjects: 42
Study 32694343 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n=15)
Number of subjects: 42
Study 32694343 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (n=12)
Number of subjects: 42
Study 35207411 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg administered orally for 12 weeks
Number of subjects: 314
Study 35207411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 32773216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n=23)
Number of subjects: 47
Study 32773216 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n=24)
Number of subjects: 47
Study 32773216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Propofol
Number of subjects: 47